Biotechnology company developing rationally designed AAV gene therapies for cardiovascular and neurological diseases
Biotechnology company developing rationally designed AAV gene therapies for cardiovascular and neurological diseases. Its proprietary ART platform uses AI and structural modeling to engineer capsids for targeted delivery of therapeutic genetic payloads. Its lead candidate, AFTX-201, is an investigational gene therapy for BAG3-associated dilated cardiomyopathy, designed for one-time intravenous administration.